Sustained-Release Injectable Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sustained-Release Injectable Drug Delivery
A review on the current status of long-acting injectables, including commercially marketed products. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s6-s13

31. C. Dai, B. Wang, and H. Zhao, Colloids Surf. B Biointerfaces 41 (2–3), 117–20 (2005).

32. M. Shameem, H. Lee, and P.P. DeLuca, AAPS PharmSci 1 (3), E7 (1999).

33. K.W. Burton et al., J. Biomater. Sci. Polym. Ed. 11 (7), 715–729 (2000).

34. J.W. Kostanski, AAPS PharmSciTech 1 (4), E27 (2000).

35. J.W. Kostanski, B.C. Thanoo, and P.P. DeLuca, Pharm. Dev. Technol. 5 (4), 585–596 (2000).

36. H.B. Ravivarapu, K. Burton, and P.P. DeLuca, Eur. J. Pharm. Biopharm. 50 (2), 263–270 (2000).

37. B.H. Woo, Pharm. Res. 18 (11), 1600–1606 (2001).

38. G. Jiang et al., J. Control. Release 79 (1–3), 137–145 (2002).

39. A. Karatas et al. J. Microencapsul. 26 (1), 63–74 (2009).

40. L. Sun et al. J. Mater. Sci. Mater. Med. 20 (10), 2035–2042 (2009).

41. J.S. Deng, Pharm. Dev. Technol. 8 (1), 31–38 (2003).

42. H. Gao et al., World J. Gastroenterol. 10 (14), 2010–2013 (2004).

43. C. Lherm, Int. J. Pharm. 84 (1), 13–22 (1992).

44. X.J. Loh, S.H. Goh, and J. Li, Biomacromolecules 8 (2), 585–593 (2007).

45. N. Bhattarai et al., J. Control. Release 103 (3), 609–624 (2005).

46. Y. Zhai et al., J. Biomater. Sci. Polym. Ed. 20 (7–8), 923–934 (2009).

47. C.B. Liu et al. J. Biomed. Mater. Res. Part B Appl. Biomater. 84B (1), 165–175 (2008).

48. S. Chen et al., Int. J. Pharm. 288 (2), 207–218 (2005).

49. M.A. Royals et al. J. Biomed. Mater. Res. 45 (3), 231–239 (1999).

50. A.C. Altamura et al., Drugs 63 (5), 493–512 (2003).

51. E.D. Knox and G.L. Stimmel, Clin. Ther. 26 (12), 1994–2002 (2004).

52. J.P. Kelleher et al. , CNS Drugs 16 (4), 249–261 (2002).

53. M.N. Samtani, A. Vermeulen, and K. Stuyckens, Clin. Pharmacokinet. 48 (9), 585–600 (2009).

54. D. Hough et al., Schizophr. Res. 116 (2–3), 107–117 (2010).

55. M. Kramer et al., Int. J. Neuropsychopharmacol. 13 (5), 635–647 (2010).

56. H.A. Nasrallah et al., Neuropsychopharmacology 35 (10), 2072–2082 (2010).

57. H. Ascher-Svanum et al., Eur. Psychiatry, in press (2010).

58. J. Lindenmayer, Neuropsychiatr. Dis. Treat. 6 , 261–267 (2010).

59. D.P. McDonnell et al., BMC Psychiatry 10, 45 (2010).

60. L. Citrome, Patient Prefer Adherence 3, 345–355 (2009).

61. H. Okada, Adv. Drug. Deliv. Rev. 28 (1), 43–70 (1997).

62. J.D. Croxtall and L.J. Scott, Drugs 68 (5), 711–723 (2008).

63. F.W. Okumu et al., Biomaterials 23 (22), 4353–4358 (2002).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here